Literature DB >> 23307531

Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.

Elizabeth M Poole1, Melissa A Merritt, Susan J Jordan, Hannah P Yang, Susan E Hankinson, Yikung Park, Bernard Rosner, Penelope M Webb, Daniel W Cramer, Nicolas Wentzensen, Kathryn L Terry, Shelley S Tworoger.   

Abstract

BACKGROUND: Approximately half of epithelial ovarian cancers are fatal within 3 years; however, roughly 35% of women survive for at least 10 years. In the Nurses' Health Study, New England Case-Control Study, Australian Ovarian Cancer Study, and NIH-AARP Diet and Health Study, we investigated potential differences in the associations with ovarian cancer risk factors by tumor aggressiveness, defined on the basis of time from diagnosis until death.
METHODS: We calculated relative risks (RR) and 95% confidence intervals (CI) for associations of known or suspected ovarian cancer risk factors with rapidly fatal (death within 3 years of diagnosis) and less aggressive tumors (all others) using Cox proportional hazards competing risks analysis (NHS and AARP) or polytomous logistic regression (NECC, AOCS). Results were combined using random effects meta-analysis.
RESULTS: Increasing age was associated with greater risk of rapidly fatal versus less aggressive disease (RR, 5-year increase: 1.39; 95% CI, 1.29-1.49 vs. RR, 1.09; 95% CI, 1.03-1.16, respectively; Pdiff < 0.0001). Oral contraceptive use was associated with a greater decreased risk of rapidly fatal (RR, 5-year increase: 0.69; 95% CI, 0.58-0.82) versus less aggressive disease (RR, 0.81; 95% CI, 0.74-0.89; Pdiff, 0.002). Conversely, increasing parity was associated only with less aggressive disease (RR per child, 0.87; 95% CI, 0.81-0.93).
CONCLUSION: In this analysis of 4,342 cases, there were clear differences in risk factors for rapidly fatal versus less aggressive ovarian tumors. IMPACT: Differences in risk factor associations by tumor aggressiveness suggests the developmental pathways through which the tumors develop and may be important for developing primary preventive strategies for the most aggressive cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307531      PMCID: PMC3596470          DOI: 10.1158/1055-9965.EPI-12-1183-T

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  Tubal ligation and survival of ovarian cancer patients.

Authors:  Min Zhang; C D'Arcy J Holman
Journal:  J Obstet Gynaecol Res       Date:  2011-11-09       Impact factor: 1.730

2.  Multiple births and risk of epithelial ovarian cancer.

Authors:  D C Whiteman; M F Murphy; L S Cook; D W Cramer; P Hartge; P A Marchbanks; P C Nasca; R B Ness; D M Purdie; H A Risch
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

3.  Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Anni Grove; Bente Lund; Niels Pallisgård; Anders Jakobsen
Journal:  Int J Gynecol Cancer       Date:  2011-12       Impact factor: 3.437

4.  Risk factors in stage III epithelial ovarian cancer: previous sterilisation is an adverse independent prognostic indicator.

Authors:  R Naik; A Nordin; P A Cross; D Hemming; A de Barros Lopes; J M Monaghan
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

5.  Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Britton Trabert; Megan A Murphy; Mark E Sherman; Joshua N Sampson; Louise A Brinton; Patricia Hartge; Albert Hollenbeck; Yikyung Park; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

6.  Identification of prognostic factors in advanced epithelial ovarian carcinoma.

Authors:  D S Chi; J B Liao; L F Leon; E S Venkatraman; M L Hensley; D Bhaskaran; W J Hoskins
Journal:  Gynecol Oncol       Date:  2001-09       Impact factor: 5.482

Review 7.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

8.  Predictors of ovarian cancer survival: a population-based prospective study in Sweden.

Authors:  Ling Yang; Asa Klint; Mats Lambe; Rino Bellocco; Tomas Riman; Kjell Bergfeldt; Ingemar Persson; Elisabete Weiderpass
Journal:  Int J Cancer       Date:  2008-08-01       Impact factor: 7.396

9.  Risk factors for epithelial ovarian cancer by histologic subtype.

Authors:  Margaret A Gates; Bernard A Rosner; Jonathan L Hecht; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2009-11-12       Impact factor: 4.897

10.  Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers.

Authors:  Bernard Rosner; Robert J Glynn; Rulla M Tamimi; Wendy Y Chen; Graham A Colditz; Walter C Willett; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2013-05-03       Impact factor: 4.897

View more
  34 in total

1.  Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.

Authors:  Nonna V Kolomeyevskaya; J Brian Szender; Gary Zirpoli; Albina Minlikeeva; Grace Friel; Rikki A Cannioto; Rachel M Brightwell; Kassondra S Grzankowski; Kirsten B Moysich
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

2.  The parity-associated microenvironmental niche in the omental fat band is refractory to ovarian cancer metastasis.

Authors:  Courtney A Cohen; Amanda A Shea; C Lynn Heffron; Eva M Schmelz; Paul C Roberts
Journal:  Cancer Prev Res (Phila)       Date:  2013-09-10

3.  Association of Ovarian Tumor β2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival.

Authors:  Tianyi Huang; Shelley S Tworoger; Jonathan L Hecht; Megan S Rice; Anil K Sood; Laura D Kubzansky; Elizabeth M Poole
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-01       Impact factor: 4.254

4.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

5.  Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy.

Authors:  Marta Szajnik; Magdalena Derbis; Michal Lach; Paulina Patalas; Marcin Michalak; Hanna Drzewiecka; Dariusz Szpurek; Andrzej Nowakowski; Marek Spaczynski; Włodzimierz Baranowski; Theresa L Whiteside
Journal:  Gynecol Obstet (Sunnyvale)       Date:  2013-04-29

6.  Statistical methods for studying disease subtype heterogeneity.

Authors:  Molin Wang; Donna Spiegelman; Aya Kuchiba; Paul Lochhead; Sehee Kim; Andrew T Chan; Elizabeth M Poole; Rulla Tamimi; Shelley S Tworoger; Edward Giovannucci; Bernard Rosner; Shuji Ogino
Journal:  Stat Med       Date:  2015-12-01       Impact factor: 2.373

Review 7.  Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study.

Authors:  Shilpa N Bhupathiraju; Francine Grodstein; Meir J Stampfer; Walter C Willett; Frank B Hu; JoAnn E Manson
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

8.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Authors:  Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

9.  Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.

Authors:  Tianyi Huang; Elizabeth M Poole; A Heather Eliassen; Olivia I Okereke; Laura D Kubzansky; Anil K Sood; John P Forman; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2016-03-25       Impact factor: 7.396

10.  Dairy food and nutrient intake in different life periods in relation to risk of ovarian cancer.

Authors:  Melissa A Merritt; Elizabeth M Poole; Susan E Hankinson; Walter C Willett; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2014-04-11       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.